Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Evan Callihan"'
Autor:
Richard Austin, Sony Rocha, Kathryn Kwant, Maria Dayao, Wade Aaron, Evan Callihan, Golzar Hemmati, Kevin Wright, Yinghua Xiao, Timothy Yu, Jessica O’Rear, Stephen Yu, Avneel Hundal, Bryan Lemon, Holger Wesche, Katrina Stephenson, Subramanian Thothathri, Rose Banzon, Eric Bragg, Willis Kwong, Hubert Situ, Taggra Jackson, Linh To, S Jack Lin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/312e28f04efa43879714a1ce7e252c2a
Autor:
Richard Austin, Thomas Evans, Jack Lin, Sony Rocha, Kathryn Kwant, Maria Dayao, Tessie Ng, Wade Aaron, Evan Callihan, Maria Gamez-Guerrero, Golzar Hemmati, Kevin Wright, Manasi Barath, Yinghua Xiao, Master Degree, Timothy Yu, Patrick Chew, Jessica O’Rear, Scott Gatto, Michael Cremin, Stephen Yu, Purbasa Patnaik, Avneel Hundal, Bryan Lemon, Holger Wesche
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/2a870365be484e02a43711d26308d88c
Autor:
Kathryn Strobel Kwant, Sony S. Rocha, Timothy Yu, Katrina Stephenson, Raphaela Rose Banzon, Sydney Vollhardt, Golzar Hemmati, Evan Callihan, Wade H. Aaron, Subramanian Thothathri, Jessica O'Rear, Eric Bragg, Willis Kwong, Hubert Situ, Avneel Hundal, Stephen Yu, Taggra Jackson, Kevin Carlin, Yinghua Xiao, Maria Rosalyn Dayao, Linh To, Nick Bergo, Kevin Wright, Richard Austin, Holger Wesche, Bryan Lemon, S. Jack Lin
Publikováno v:
Cancer Research. 82:2861-2861
CD3-targeted T cell engagers are potent anti-tumor therapies, but their development often requires management of cytokine release syndrome (CRS). One strategy to reduce CRS is subcutaneous dosing, which is hypothesized to mitigate CRS by reducing the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f688ce9d413f959d61e29475d25a2de
https://doi.org/10.1158/1538-7445.am2022-2861
https://doi.org/10.1158/1538-7445.am2022-2861
Autor:
Kevin Wright, Jack Lin, Richard C. Austin, Maria Dayao, Lemon Bryan D, Master Degree, Michael Cremin, Stephen Yu, Purbasa Patnaik, Jessica O’Rear, Holger Wesche, Golzar Hemmati, Sony Rocha, Maria Gamez-Guerrero, Tessie M. Ng, Yinghua Xiao, Avneel Hundal, Scott Gatto, Kathryn Kwant, Tom Evans, Timothy Yu, Manasi Barath, Patrick Chew, Evan Callihan, Wade Aaron
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Epithelial cell adhesion molecule (EpCAM) is highly expressed in many solid tumors. However, therapeutics targeting EpCAM have had limited clinical utility or failed in clinical development likely due to the expression of EpCAM in normal t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e0492817e767fbfa910f853a5faa9b
https://doi.org/10.1136/jitc-2020-sitc2020.0632
https://doi.org/10.1136/jitc-2020-sitc2020.0632
Autor:
Laura Sun, Patrick Ng, Abdel Kareem Azab, Wade Aaron, Evan Callihan, Che-Leung Law, Golzar Hemmati
Publikováno v:
Blood. 138:1185-1185
Introduction B-cell maturation antigen (BCMA) is a cell surface receptor highly and selectively expressed on normal plasma cells and transformed plasma cells in multiple myeloma (MM) patients. Upon ligand binding, BCMA initiates signals that promote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d694bff5d66859756de4a783da9942a
https://doi.org/10.1182/blood-2021-151880
https://doi.org/10.1182/blood-2021-151880
Autor:
Katrina Stephenson, S. Jack Lin, Kevin Wright, Hubert Situ, Richard C. Austin, Lemon Bryan D, Yinghua Xiao, Subramanian Thothathri, Sony Rocha, Holger Wesche, Taggra Jackson, Avneel Hundal, Wade Aaron, Evan Callihan, Linh To, Maria Dayao, Eric Bragg, Willis Kwong, Golzar Hemmati, Timothy Yu, Stephen Yu, Kathryn Kwant, Jessica O’Rear, Rose Banzon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCD3-targeted T cell engagers are potent anti-tumor therapies, but their development often requires management of cytokine release syndrome (CRS). Subcutaneous dosing is a promising strategy to reduce CRS, but its application is limited by i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df20fa88b82841bb092b3d42592a0cec
https://doi.org/10.1136/jitc-2021-sitc2021.867
https://doi.org/10.1136/jitc-2021-sitc2021.867
Autor:
Timothy Yu, Raphaela Rose Banzon, Sony Rocha, Holger Wesche, Stephen Yu, Subramanian Thothathri, Yinghua Xiao, Jessica O’Rear, Kathryn Kwant, Kevin Wright, Purbasa Patnaik, Manasi Barath, Richard J. Austin, Avneel Hundal, S. Jack Lin, Golzar Hemmati, Lemon Bryan D, Tessie M. Ng, Scott Gatto, Wade Aaron, Evan Callihan, Linh To, Maria Dayao, Eric Bragg
Publikováno v:
Cancer Research. 81:933-933
T cell engagers have compelling clinical activity, but their use is limited by the availability of tumor targets with minimal normal tissue expression. Conditionally active T cell engagers designed to be active only in the tumor and to spare normal t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c82d09e115f10025f86264aee89fc782
https://doi.org/10.1158/1538-7445.am2021-933
https://doi.org/10.1158/1538-7445.am2021-933
Autor:
Stephen Yu, Kevin M. Wright, Jessica O’Rear, Manasi Barath, Wade Aaron, Lemon Bryan D, Morgan Thompson, Scott Gatto, Evan Callihan, Timothy Yu, Purbasa Patnaik, Holger Wesche, Che-Leung Law, Richard J. Austin, Lihn To, Golzar Hemmati, Yinghua Xiao
Publikováno v:
Cancer Research. 81:913-913
FLT3 (fms related receptor tyrosine kinase 3) is a cell surface protein expressed in hematopoietic stem and progenitor cell populations1. FLT3 RNA is overexpressed in greater than 95% of acute myeloid leukemia (AML) samples2, and FLT3 mutations are f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89d12e21da0bce7ca52255eafb28b34c
https://doi.org/10.1158/1538-7445.am2021-913
https://doi.org/10.1158/1538-7445.am2021-913
Autor:
Golzar Hemmati, Holger Wesche, Richard J. Austin, Thomas Evans, Mary Ellen Molloy, Kathryn Kwant, Llewelyn Lao, Vaishnavi Ganti, Stephen Yu, Jessica O’Rear, Che-Leung Law, Lemon Bryan D, Michael Cremin, Wade Aaron, Evan Callihan, Laura Sun, Manasi Barath, Timothy Yu, Maria Gamez
Publikováno v:
Molecular Cancer Therapeutics. 18:C033-C033
HPN328: An Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer Delta-like protein 3 (DLL3) is a Notch inhibitory ligand is expressed in more than 70% of small cell lung cancers (SCLCs), while there is little to no surface expression in n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b878b5c536444ed9bad242896fa81bb
https://doi.org/10.1158/1535-7163.targ-19-c033
https://doi.org/10.1158/1535-7163.targ-19-c033
Autor:
Timothy Yu, Yinghua Xiao, Purbasa Patnaik, Kathryn Kwant, Maria Gamez Guerrero, Evan Callihan, Stephen Yu, Holger Wesche, Wade Aaron, A. Jones, Manasi Barath, Che-Leung Law, Kenneth Sexton, Katrine Moldt, Lemon Bryan D, Thomas J. Evans, Richard C. Austin, Golzar Hemmati, Llewelyn Lao
Publikováno v:
Blood. 132:3225-3225
About 31,000 new cases of multiple myeloma (MM) will be diagnosed in the US in 2018. In addition to chemotherapeutic agents, several targeted therapies utilizing distinct mechanisms of action, e.g., proteasome inhibitors (bortezomib, carfilzomib, ixa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45ee28fea42c4f22a7f2ab1287f9dcb8
https://doi.org/10.1182/blood-2018-99-113921
https://doi.org/10.1182/blood-2018-99-113921